Roivant Sciences Ltd (NAS:ROIV)
$ 12.48 -0.23 (-1.81%) Market Cap: 9.08 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 61/100

Roivant Sciences Ltd to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis Call Transcript

Mar 15, 2023 / 12:00PM GMT
Release Date Price: $8.59 (+7.91%)
Operator

Good day, and thank you for standing by. Welcome to the ADORING 2 Data Release Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.

Stephanie Lee Griffin
Roivant Sciences Ltd. - VP of Special Projects

Good morning, and thank you for joining today's call to review Phase III results from ADORING 2, 1 of 2 pivotal Phase III trials of VTAMA cream with the treatment of atopic dermatitis. I'm Stephanie Lee of Roivant Sciences. Presenting today, we have Matt Gline, CEO of Roivant; Todd Zavodnick, CEO of Dermavant; and Phil Brown, Chief Medical Officer of Dermavant.

For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot